30 results about "Abnormal liver function" patented technology

The present disclosure relates to a herbal compound extract to moderate diabetes with liver necrosis and fibrosis and applications thereof wherein a herbal compound consists of 10 to 20 units rhizome of Dendrobium nobile Lindl, 6 to 12 units fruiting body of Antrodia camphorata, 12 to 20 units root of Panax ginseng C. A. Mey, 10 to 30 units root of Rehmannia glutinosa Libosch, 15 to 30 units rhizome of Salvia miltiorrhiza Bge., 6 to 12 units all of Pheretima asperfillm (E. Perrier), 10 to 30 units root of Pueraria mirifica, 8 to 15 units fruit of Schisandra chinensis (Turcz.) Baill and 6 to 8 units rhizome of Glycyrrhiza uralensis Fisch and the herbal compound extract is able to moderate symptoms comprising hyperglycemia, hyperlipidemia, abnormal liver function about liver necrosis and fibrosis due to the diabetes.

The invention relates to a traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression. The traditional Chinese medicine has obvious treatment effects on symptoms such as deprementia, chest hypochondriac pain, lassitude, upset irritability, abdominal distension and diarrhea and the like of the liver constraint and spleen deficiency type post-strokedepression, improves spirit and emotions, promotes the recovery of neural functions of stroke patients, and does not have obvious toxic or side effects such as dizziness, hypodynamia, somnolence, drymouth, constipation, hypotension, abnormal liver functions, epilepsy, cardiac arrhythmia, toxicosis and the like. The technical scheme is that: the traditional Chinese medicine is prepared form the following raw materials by weight: 10 to 14g of bupleurum, 9 to 11g of turmeric root-tuber, 10 to 14g of Chinese angelica, 10 to 14g of white paeony root, 13.5 to 16.5g of fried largehead atractylodes rhizome, 9 to 11g of Indian buead, 18 to 22g of codonopsis pilosula, 9 to 11g of tangerine peel, 9 to 11g of bamboo shavings, 13.5 to 16.5g of gardenia, 4.5 to 5.5g of mint and 2.7 to 3.3g of liquoricroot. The traditional Chinese medicine is prepared into decoction by the conventional soaking, decocting and filtering or is prepared by directly blending market-sold single Chinese medicinal formulaparticles. The traditional Chinese medicine has the advantages of high reliability, high safety, high flexibility, no dependence and the like.

The invention relates to a non-invasive apparatus system for monitoring drug hepatotoxicity, and its uses in monitoring drug-induced hepatotoxicity and abnormal liver function.

The invention discloses the application of a traditional Chinese medicine composition in the preparation of medicine for treating abnormal liver function. The traditional Chinese medicine composition is composed of ginseng, sealwort, atractylodes rhizome, flavescens, poria cocos, radix radix radix Radix Polygoni Multiflori, rehmannia glutinosa, cornel officinalis, berberine, perrin and the like. Experiments have proved that the medicine of the invention can effectively treat abnormal liver function.

The invention relates to novel application of known compound coniferyl ferulate, and belongs to the technical field of medicines. Completed animal model tests indicate that the abnormal liver function of a CC14 induced mouse liver fibrosis model can be remarkably improved after coniferyl ferulate intervenes, the serum aspartate amino transferase and the level of serum total bilirubin can be reduced, the content of hydroxyproline can be reduced, the activation of hepatic stellate cells can be inhibited, type I collagen expression can be reduced, and collagen deposition of hepatic tissues can be inhibited.

The invention provides applications of pegylated artesunate shown as the formula (I) in preparing medicines capable of resisting hepatic pathological changes. According to the applications, pegylated artesunate can obviously reduce the hepatic fibrosis condition and abnormal liver function of hepatic fibrosis rats caused by carbon tetrachloride, reduce the amount of the serum fibrosis markers such as hyaluronidase (HA), laminin (LN) and procollagen III (PC-III), reduce the amount of alamine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum, reduce the contents of malondialdehyde (MDA) and hydroxyproline (Hyp) of the liver tissue, and effectively prevent the development of liver fibrosis and promote the reversion of liver fibrosis, and has the significant differences compared with artesunate under the same dosage. In addition, the pegylated artesunate is good in water solubility, high in bioavailability, and long in half-life period, and the administration times can be reduced. The formula (I) is shown as follows.